Title

Authors

Document Type

Article

Publication Date

1-1-2012

Abstract

The increased number of cases of type 2 diabetes mellitus (both diagnosed and undiagnosed) parallels the current epidemic of obesity in the United States. Despite receiving treatment, many patients do not achieve established therapeutic goals. Type 2 diabetes mellitus is a progressive disease characterized by multiple abnormalities that extend beyond β-cell dysfunction and insulin resistance. Incretin-based agents, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become important options in the therapeutic paradigm for patients with type 2 diabetes mellitus. The author reviews physiologic mechanisms of the incretin system and discusses the practical application of GLP-1 receptor agonists and DPP-4 inhibitors in improving GLP-1 dynamics in patients with type 2 diabetes mellitus.

Publication Title

Journal of the American Osteopathic Association

Volume

112

Issue

1 Supplement 1

First Page

S2

Last Page

S6

PubMed ID

22267300

Comments

This article was published in Journal of the American Osteopathic Association, Volume 112, Issue 1, Supplement 1, January 2012, Pages S2-6.